NovaTarg was founded by Ken Batchelor in the Fall of 2009 with the mission to discover and develop innovative medicines to treat metabolic diseases and cancer.

NovaTarg is located at the First Flight Venture Center in Research Triangle Park, NC.

NovaTarg’s novel drug discovery approach has enabled identification of a series of tissue selective AMPK activators.

Our first drug candidate for type 2 diabetes, NT1195, is undergoing nonclinical safety evaluation